Circulating Tumor Cells (CTC), Lung Cancer
The Circulating Tumor Cell (CTC) test provides a measurement of tumor (cancer) cells that are circulating in the bloodstream. It provides enumeration of circulating tumor cells (CTC) of epithelial origin in whole blood originating from tumors/cancers. The circulating tumor cells are of epithelial origin and are not normally found in blood and are extremely rare in individuals with no malignancy. Since tumor cells have a tendency to metastasize, blood would be one of the travel routes. Therefore, CTCs are mainly found in metastatic cancers. The CTC test measures the number of tumor cells that are separated from the tumor and are circulating freely in the bloodstream. This assay uses specific markers to detect breast epithelial tumor cells in blood, and it is specific for epithelial cell tumor markers of breast cancer origin. Therefore, this test is mainly utilized to determine and monitor the efficacy of treatment (such as chemotherapy) and prognosis of patients with metastatic cancer of the breast.
In breast cancer, studies indicate that results of fewer than 5 CTCs has a mean survival rate of 2 ½ years. Patients with > or = 5 CTCs had a median overall survival rate of about 11 months and any individual with more than 50 CTCs had a shorter progression-free survival (PFS) and poorer overall survival (OS) for metastatic breast cancer. The individuals with greater than 50 CTCs had a survival rate of approximately 6 months. It has been stated that the CTC test is a better predictor of active tumor metastasis than current imaging methods. The reason for this is due to the fact that imaging could represent historical tumors while CTCs indicate the recurrence of metastasizing tumors much quicker.
- Disease and treatment management efficacy of treatment (such as chemotherapy) and prognosis of patients with metastatic cancer of the breast
- Circulating Tumor Cell results assist the physician in predicting the advanced breast cancer patient's response to treatment and overall survival rate
- Breast cancer management
- Subjects with less than 5 CTCs have survival rate of 2 ½ years
- Subjects with between 5 and 50 CTCs indicates a median overall survival rate of about 11 months
- Individual with more than 50 CTCs have shorter progression-free survival (PFS) and poorer overall survival (OS) of approximately 6 months
<5 CTC/7.5mL of whole blood (Negative for CTC)
10 mL room-temperature whole blood (CellSave Preservative Tube); 7.5 mL minimum volume. Ship promptly; specimen must be tested within 96 hours. Patient history pertinent to breast cancer is required to perform this test.
- N Engl J Med. 2004; 351(8):781-91. [PMID: 15317891]
- Semin Oncol. 2006 Jun;33(3 Suppl 9):S9-14. [PMID: 16797376]
- Curr Treat Options Oncol. 2007 Feb;8(1):89-95. [PMID: 17634836]
- J Clin Oncol. 2005; 23(7):1420-30. [PMID: 15735118]